Benign Prostatic Hyperplasia Market By Treatment Type (Pharmacological Treatment {Alpha Blockers, 5-alpha-reductase Inhibitors, Combination Therapy, Phytotherapy}, Minimally Invasive Procedures {UroLift System, Rezūm Therapy, Prostatic Artery Embolization}, Surgical Treatment {Transurethral Resection of the Prostate, Laser Surgery, Open Prostatectomy}), By Dosage Form (Oral Immediate-Release, Oral Extended-Release, Others), By Diagnostic Method (Digital Rectal Exam, Prostate-Specific Antigen Test, Ultrasound, Urinary Flow Study, Cystoscopy), By End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Benign Prostatic Hyperplasia Market accounted for USD 12.9 Billion in 2024 and USD 13.51 Billion in 2025 is expected to reach USD 21.4 Billion by 2035, growing at a CAGR of around 4.7% between 2025 and 2035. Benign Prostatic Hyperplasia (BPH) refers to the benign enlargement of the prostate gland, which affects older men. It causes urinary symptoms such as frequent urination, loss of strength with the urine stream, and inability to empty the bladder, which is caused by pressure on the urethra. Hormonal imbalances, in this case, high levels of dihydrotestosterone (DHT) as one gets older, are the driving factor of the condition.

Current treatments include medications, minimally invasive therapies, and surgery. The prospect of BPH management is quite encouraging since various aspects and concepts have gained popularity, and they include personalized medicine, safer use of drugs, and intricate laser or robot-aided interventions. Also, an increase in awareness and an aging worldwide population will trigger further advancements in diagnostics and treatment. 

Industry Experts Opinion

"BPH is not just about prostate size; it's about symptom burden and obstruction. We now have advanced diagnostic tools like uroflowmetry and MRI to tailor treatment, ensuring men receive the most effective therapy with minimal side effects."

• Dr. Claus Roehrborn, Professor and Chair of Urology, UT Southwestern Medical Center

Report Scope:

Market Dynamics

The rising geriatric male population is increasing BPH prevalence and demand for effective treatments.

The proliferation in the population of aging men across the world is one of the major contributors to the expansion of the Benign Prostatic Hyperplasia Market. BPH occurs mainly in men past the age of 50, with the rate rising exceptionally high among men past 60. With the increase in life expectancy in the whole world, many aged men are on the increase, and this has contributed to more cases of enlarged prostate of prostate gland. As per the clinical evidence, at least 50 percent of men above 60 have been reported to have symptoms of BPH. These are frequent urination, nocturia, poor flow of urine, and incomplete emptying of the bladder.

The healthcare consequences of treating the urinary disorder associated with age have become more evident. This, in turn, is leading to rising demand for the diagnosis and treatment options of BPH. This population trend is affecting increased consumption of pharmacological treatment and surgery. Also, men's health campaigns are enhancing the rate of early diagnosis. Healthcare staff and governments are committing to spending more on urology services. This development trend is likely to carry the BPH market. Therefore, the growth of the elderly men's population is one of the main drivers of the growth trend of the Benign Prostatic Hyperplasia Market.

Advancements in minimally invasive procedures improve outcomes and patient preference over traditional surgeries.

The Benign Prostatic Hyperplasia Market is being transformed through innovations of minimally invasive procedures. Other technologies provide a quick recovery, fewer complications, and these technologies include the UroLift System, RezUM water vapor therapy, and prostatic embolization. The treatments minimize the likelihood of hospitalization, and they reduce the occurrence of significant surgical dangers. Patients are increasingly making use of these techniques over the traditional methods, such as the TURP, as it induces less discomfort, and recovery to normal life is achieved within a shorter period. Clinical results demonstrate symptomatic relief and an increase in quality of life following the procedure.

Moreover, these processes tend to maintain sexual performance in a better way compared to traditional operations. These innovations are bringing a change in the preference for treatment in the global market. Medical practitioners are increasingly using such technologies in their outpatient facilities. There is also an increase in reimbursement coverage of advanced procedures, particularly in developed countries. Consequently, this is seeing minimally invasive therapies becoming the new normal state of care. They are becoming more and more popular, which also increases the volumes of procedures and the devices. These are the inventions that are strongly driving the market of Benign Prostatic Hyperplasia.

High cost of advanced therapies limits access in low- and middle-income regions.

Though the Benign Prostatic Hyperplasia Market is transforming as it progresses towards superior treatment, the cost of the treatment poses a significant barrier. Branded drugs and minimally invasive procedures are usually high-priced items. In low and middle-income countries (LMICs), these options are limited by the scarcity of healthcare budgets and out-of-pocket payment methods for healthcare. In populations that enjoy insurance coverage, the co-payments are high, and this may discourage the use of newer therapies by the patient. Public hospitals might not have the infrastructure or the skilled staff to perform complicated operations such as laser or even embolization. Consequently, a patient in such areas tends to treat themselves using simple drug therapy or neglect.

This contributes to further complications and lowers the quality of life. The market segment of cost-sensitive consumers cannot easily implement modern technologies, even though there are clinical advantages. The difference in price among geographies also restrains the consistent expansion of the worldwide BPH market. Besides, there is access to cheap generic medication that contributes to the unwillingness to do it with a newer drug. The reduction of this gap related to affordability is the key to balanced expansion across the globe. High-cost barrier is another constraint with regard to the betterment of the Benign Prostatic Hyperplasia Market.

Technological innovations in laser and implantable devices promise better, safer BPH management.

There are high opportunities in the Benign Prostatic Hyperplasia Market due to the ever-increasing medical device technology. Newer technologies such as laser-assisted enucleation (HoLEP) and implantable prostatic implants are changing the treatment environment. Such technologies are more accurate, limit blood loss, and accelerate the recovery of patients. They also foster accuracy and safety in surgical procedures and make them more efficient and non-critical. An example of this is laser surgery, which is now regarded as an excellent alternative for patients at substantial risk. Surgery outcomes are further being enhanced by the emergence of robotics and image-guided systems.

The innovations are especially helpful with complex or large prostates. The device manufacturers are also putting their emphasis on compact and easy-to-use systems since there is an increase in demand for day-care surgical procedures. This not only lends output to clinical outcomes but also lessens the burden on a hospital. Product adoption is increasing due to regulatory clearances and the increasing acceptance in clinical practice. Competitive differentiation and market expansion are happening due to such technological breakthroughs. Consequently, the Benign Prostatic Hyperplasia Market would gain a lot through the further development of treatment equipment.

Untapped emerging markets offer potential for the expansion of low-cost and alternative treatment options.

The Benign Prostatic Hyperplasia Market has a great growth potential in terms of emerging economies. These areas encompassing sections of Asia-Pacific, Latin America, and Africa boast a huge aging population with minimal availability to specialized urological services. Due to increased awareness of prostate health, there has been an increased need for desire to undergo diagnosis and treatment at affordable rates. Those companies that sell cheap drugs and minimally invasive devices can get an opportunity to acquire a new clientele. Generic substitution and a localized production may assist in further reducing the expenses.

There is also the expansion of care in underserved areas, such as telehealth and mobile clinics. Still, governments are slowly pouring money into health care architecture and insurance. The training of the BPH procedures and the provision of updated tools can be performed with the help of public-private partnerships. The presence of medical tourism in India and Thailand also enhances better access to superior treatment at budgeted rates. Global players are now targeting these emerging economies, which are their long-term growth targets. As such, this growth in these markets may be an important aspect in enhancing the presence of the Benign Prostatic Hyperplasia Market worldwide.

Segment Analysis

Based on the Treatment Type, the Benign Prostatic Hyperplasia Market has been classified into Pharmacological Treatment, Minimally Invasive Procedures, and Surgical Treatment. Pharmacological treatment is the major competent piece in the market of Benign Prostatic Hyperplasia (BPH) because it is a non-invasive measure with an enormous range of availability.

The most commonly prescribed are the alpha blockers and the 5-alpha-reductase inhibitors, which provide effective relief of symptoms with very few side effects. The idea of combination therapy is becoming popular in treating moderate and severe cases of BPH. Brand new, minimally invasive procedures such as UroLift and RezUM are gaining rapid growth due to the improved patient outcomes and reduced patient recovery time. TURP and laser surgery are still used as surgical interventions for extreme or drug-resistant cases. However, preference is steadily shifting toward less invasive alternatives.

Based on the Dosage Form, the Benign Prostatic Hyperplasia Market has been classified into Oral Immediate-Release, Oral Extended-Release, and Others. The most popular dosage form in the Benign Prostatic Hyperplasia Market is oral immediate-release forms because of their convenience, fast performance, and popularity among physicians and patients.

These include widely used medications like Tamsulosin and Finasteride. Oral extended-release tablets are also catching up, particularly in long-term management, and are more compliant and have fewer side effects. The other category, such as experimental forms of drugs, such as transdermal patches or injectables, is yet to grow as big as the R&D is still ongoing, but there is an opportunity. The pharmaceutical segment of the BPH market is mainly driven by oral dosage forms.

Regional Analysis

The North America Benign Prostatic Hyperplasia Market holds the highest share, which has been attributed to its advanced healthcare system, high awareness rates, and the presence of aging men. Early diagnosis and the availability of high-end treatment methods like the minimally invasive procedures and cooperative drug therapy have remained high in the region. Domination of the region is also backed by the presence of major players in the market and the frequent launch of products. The U.S., especially, constitutes a large segment of this market, which is backed by the promotion of favorable reimbursement and sufficient clinical research. All in all, the robust healthcare system in North America qualifies it to be the largest contributor to the global BPH market.

The Asia-Pacific Benign Prostatic Hyperplasia Market is also becoming the most dynamic, due to the increasing awareness of health, expanding access to healthcare services, and an elderly male population surge. The maximally invasive treatment and pharmacological treatment are getting more popular in countries such as China, India, and Japan. The market is being fueled by government efforts to shore up urological treatment and increasing expenditure in healthcare infrastructure. Moreover, the low prices of generics and medical tourism are another factor that increases the possibilities of growth in this area. The Asia-Pacific region holds an enormous, underinvested population, and it is massively urbanizing, making it forecasted to have the greatest CAGR in the BPH market.

Competitive Landscape

The Benign Prostatic Hyperplasia Market comprises well-established pharmaceutical giants, medical device companies, and some start-up firms in the bio-technology industry. Major competitors are GlaxoSmithKline, Astellas Pharma, Pfizer, Merck & Co., AbbVie, Boston Scientific, Teleflex, and Allergan. Such firms are concentrating on the growth of the product line by developing new formulations in drugs, innovation in the devices, as well as solutions towards minimally invasive treatment. As such, companies such as Boston Scientific and Teleflex are developing such technology as the UroLift and Rezum systems to support a rise in outpatient procedures. Drug firms like Pfizer and Merck are continuing to control the market through the marketing of popular oral drugs and label extension.

Strategic alliances, mergers, and acquisitions are extremely popular, such as the acquisition of Allergan by AbbVie in a bid to gain much market share and access to urology solutions. Clinical trials are also another area where many players are investing to prove the long-term effectiveness of the new therapies and devices. One of the drivers of growth will be geographic, especially to reach emerging markets, as these remain unexplored areas of unmet needs. On its part, the BPH market is experiencing new competitive dynamics composed of innovation, affordability, and global coverage.

Benign Prostatic Hyperplasia Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Recent Developments:

• In February 2024, the FDA approved UroLift 2.0 with enhanced delivery for larger prostates, aiming to improve procedural efficiency and patient outcomes. This upgrade is expected to expand its adoption among urologists treating complex BPH cases.
• In January 2024, positive real-world data from European studies showed high efficacy of the iTind device in relieving urinary obstruction. This clinical validation is expected to boost its adoption as a minimally invasive alternative for BPH treatment.

Report Coverage:

By Treatment Type

• Pharmacological Treatment
  • Alpha Blockers
  • 5-alpha-reductase Inhibitors
  • Combination Therapy
  • Phytotherapy
• Minimally Invasive Procedures
  • UroLift System
  • Rezūm Therapy
  • Prostatic Artery Embolization
• Surgical Treatment
  • Transurethral Resection of the Prostate
  • Laser Surgery
  • Open Prostatectomy

By Dosage Form

• Oral Immediate-Release
• Oral Extended-Release
• Others

By Diagnostic Method

• Digital Rectal Exam
• Prostate-Specific Antigen Test
• Ultrasound
• Urinary Flow Study
• Cystoscopy

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Homecare
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• GlaxoSmithKline plc
• Astellas Pharma Inc.
• Abbott Laboratories
• Pfizer Inc.
• Merck & Co., Inc.
• Eli Lilly and Company
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Allergan
• Novartis AG
• Bayer AG
• Ferring Pharmaceuticals
• Teleflex Incorporated
• Boston Scientific Corporation

Frequently Asked Questions (FAQs)